S.D. Admin. R. 44:20:01:04 - Category II reportable diseases and conditions

Category II reportable diseases and conditions include:

(1) Acute flaccid myelitis;

(2) Anaplasmosis (Anaplasmaphagocytophilum);

(3) Arboviral encephalitis, meningitis or infection (Eastern equine, Western equine, California serogroup, St Louis, Japanese, Powassan, West Nile virus, Chikungunya, Colorado tick fever, Zika virus);

(4) Babesiosis (Babesia spp);

(5) Campylobacteriosis (Campylobacter spp.);

(6) Chancroid (Haemophilus ducreyi);

(7) Carbon monoxide poisoning;

(8) Chicken pox/Varicella (herpesvirus);

(9) Chlamydia infections (Chlamydia trachomatis);

(10) Cholera (Vibrio cholerae);

(11) Cryptosporidiosis (Cryptosporidium parvum);

(12) Coccidioidomycosis (Coccidioides spp);

(13) Cyclospora (Cyclospora cayetanensis);

(14) Dengue viral infection (flaviviruses);

(15) Drug resistant organisms:

(a) Vancomycin-resistant Staphylococcus aureus (VRSA);

(b) Carbapenemase-producing organisms,_____ including Entrobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa;

(c) Candida auris;

(16) Ehrlichiosis (Ehrlichia spp.);

(17) Giardiasis (Giardia lamblia);

(18) Gonorrhea (Neisseria gonorrhoeae);

(19) Haemophilus influenzae, invasive disease;

(20) Hantavirus pulmonary syndrome and Hantavirus pulmonary infection (Hantaviruses);

(21) Hemolytic uremic syndrome;

(22) Hepatitis, viral types A, B, and C, including all molecular Hepatitis C results;

(23)

(24) Human immunodeficiency virus (HIV) infection; including:

(a) AIDS (Stage III infection);

(b) CD4 counts in HIV infection persons;

(c) HIV viral loads; and

(d) Pregnancy in HIV infected females;

(e) HIV gene sequencing;

(f) HIV antiviral resistance;

(g) Confirmatory results, positive or negative, following a reactive HIV screening test;

(25) Influenza:

(a) Laboratory confirmed cases;

(b) Influenza-associated deaths;

(c) Influenza-associated hospitalizations; and

(d) Weekly reports of number of rapid antigen influenza positive tests and total number tested;

(26) Lead, e all blood levels;

(27) Legionellosis (Legionella spp.);

(28) Leprosy/Hansen's disease (Mycobacterium leprae);

(29) Leptospirosis (Leptospira);

(30) Listeriosis (Listeria monocytogenes);

(31) Lyme disease (Borrelia burgdorferi);

(32) Malaria (Plasmodium spp.");

(33) Melioidosis (Burkholderia pseudomallei)

(34) Mumps;

(35) Pertussis (Bordetellapertussis);

(36) Pesticide-related illness and injury, acute;

(37) Psittacosis (Chlamydia psittaci);

(38) Q fever (Coxiella burnetii);

(39) Salmonellosis (Salmonella sppi);

(40) Shigellosis (Shigella sppi);

(41) Silicosis;

(42) Spotted Fever Rickettsiosis (Rickettsia spp);

(43) Streptococcus pneumoniae, invasive;

(44) Syphilis (Treponema pallidum), including primary, secondary, latent, early latent, late latent, neurosyphilis, non-neurological, stillbirth, and congenital;

(45) Tetanus (Clostridium tetani);

(46) Toxic shock syndrome (Streptococcal and non-Streptococcal);

(47) Transmissible spongiform encephalopathies, such as Creutzfeldt-Jakob disease;

(48) Trichinosis (Trichinella spiralis);

(49) Tuberculosis (Mycobacterium tuberculosis or Mycobacterium bovis): Latent infection in a high risk person;

(50) Typhoid (Salmonella typhi); and

(51) Vibriosis (Vibrionaceae [other than toxigenic Vibrio cholerae O1 or O139, which are reportable as cholera]).

Notes

S.D. Admin. R. 44:20:01:04

20 SDR 69, effective 11/17/1993; 23 SDR 60, effective 10/31/1996; 28 SDR 92, effective 12/30/2001; 29 SDR 87, effective 12/22/2002; 30 SDR 87, effective 12/7/2003; 31 SDR 89, effective 12/27/2004; 33 SDR 106, effective 12/26/2006; 34 SDR 179, effective 12/24/2007; 38 SDR 8, effective 8/1/2011; 39 SDR 203, effective 6/10/2013; 42 SDR 77, effective 11/30/2015; 42 SDR 173, effective 7/1/2016; 50 SDR 012, effective 8/8/2023

General Authority: SDCL 34-1-17, 34-22-9, 34-22-12, 34-23-13.

Law Implemented: SDCL 34-22-9, 34-22-12, 34-23-13.